Position in NVS
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$1,625,029
+$59,495 QoQ
Shares Held
10,369
+1.2% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
#484
of 1,603 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Bridgewater Advisors Inc. holds $24,557,436 across 14 Drug Manufacturers - General names. NVS ranks #6 (6.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
22,989 | $5,838,516 | |
| 2 | LLY |
ELI LILLY & Co
|
3,983 | $4,777,330 | |
| 3 | MRK |
Merck & Co., Inc.
|
23,905 | $3,071,792 | |
| 4 | ABBV |
AbbVie Inc.
|
9,702 | $2,441,411 | |
| 5 | AMGN |
Amgen Inc
|
5,459 | $1,976,813 | |
| 6 | NVS |
Novartis AG
This page
|
10,369 | $1,625,029 | |
| 7 | PFE |
Pfizer Inc
|
62,287 | $1,499,870 | |
| 8 | AZN |
Astrazeneca PLC
|
4,442 | $842,292 |
All Filings in NVS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,625,029 | 10,369 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $1,565,534 | 10,249 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,532,976 | 11,119 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $1,412,435 | 11,014 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $1,340,306 | 11,076 | Shares | Sole | 2025-08-05 | |
| 2025-03-31 | $1,227,283 | 11,009 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $1,102,814 | 11,333 | Shares | Sole | 2025-01-16 | |
| 2024-09-30 | $1,313,873 | 11,423 | Shares | Sole | 2024-10-31 | |
| 2024-06-30 | $1,192,032 | 11,197 | Shares | Sole | 2024-08-02 | |
| No filing history on record for this holder in this stock. | ||||||